Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04641442 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
A Phase 2 study of NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 20
- Study locations
NCT04641442 is a Phase 2 study of NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 17 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT04641442, a Phase 2 study of NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MAS825
Study Locations (20)
Other
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Prague
- Ustav Imunologie 2 LF UK a FN Motol - Prague
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Chiba
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - London
- Great Ormond Street Hospital - London
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Cincinnati Childrens Hospital - Cincinnati
Pennsylvania
- Childrens Hospital of Philadelphia - Philadelphia
- Children´s Hospital of Philadelphia - Philadelphia
Texas
- Texas Childrens Hospital - Houston
- Texas Children´s Hospital - Houston
Washington
- Seattle Childrens Hospital - Seattle
- Seattle Children´s Hospital - Seattle
RM
- Bambino Gesu Hospital - Roma
- Novartis Investigative Site - Roma
CZ
- Centrum detske revmatologie a autoinflamatornich onemocneni - Prague
Catalonia
- Hospital Clinic Barcelona - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2032-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04641442
The ClinicalTrials.gov registry entry for NCT04641442 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04641442 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04641442 about?
NCT04641442 is a clinical study titled "Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations". This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
What is the current status of trial NCT04641442?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2020-12-18. Estimated completion is 2032-04-07.
What conditions does trial NCT04641442 study?
This clinical trial studies the following conditions: NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations.
What interventions are being tested in trial NCT04641442?
The interventions under investigation include: Placebo (BIOLOGICAL), MAS825 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04641442?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04641442 being conducted?
This trial has 20 study locations across Ohio, Pennsylvania, Texas, Washington, CZ. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.